COVID-19 and the concept of thrombo-inflammation: Review of the relationship between immune response, endothelium and coagulation
E de Maistre, P Savard, PG Guinot - Journal of Clinical Medicine, 2023 - mdpi.com
COVID-19, caused by the SARS-CoV-2 virus, has revealed a complex interplay between
inflammation and coagulation, leading to the emergence of the concept of thrombo …
inflammation and coagulation, leading to the emergence of the concept of thrombo …
[HTML][HTML] 2023 ISTH update of the 2022 ISTH guidelines for antithrombotic treatment in COVID-19
S Schulman, DM Arnold, CA Bradbury… - Journal of thrombosis …, 2024 - Elsevier
Based on emerging evidence from the COVID-19 pandemic, the International Society on
Thrombosis and Haemostasis (ISTH) guidelines for antithrombotic treatment in COVID-19 …
Thrombosis and Haemostasis (ISTH) guidelines for antithrombotic treatment in COVID-19 …
Appropriate thromboprophylaxis strategy for COVID-19 patients on dosage, antiplatelet therapy, outpatient, and postdischarge prophylaxis: a meta-analysis of …
J Meng, H Tang, Y Xiao, W Liu, Y Wu… - … Journal of Surgery, 2024 - journals.lww.com
Background: There was controversy surrounding the optimal thromboprophylaxis strategy
for coronavirus disease 2019 (COVID-19) patients. This included debates on the dosage of …
for coronavirus disease 2019 (COVID-19) patients. This included debates on the dosage of …
Low-molecular-weight heparin for the prevention of clinical worsening in severe non-critically ill COVID-19 patients: a joint analysis of two randomized controlled trials
MA Wu, C Del GIovane, R Colombo, G Dolci… - Internal and emergency …, 2024 - Springer
Abstract Coronavirus disease 2019 (COVID-19) carries a high risk of vascular thrombosis.
However, whether a specific anticoagulation intensity strategy may prevent clinical …
However, whether a specific anticoagulation intensity strategy may prevent clinical …
Reply to “Embracing imatinib: a novel approach to safeguarding the endothelial barrier in patients with COVID-19”
X Wu, J Shi - Angiogenesis, 2023 - Springer
We would like to thank the interest of Kow et al. in our study. In the letter, they expressed
their skepticism that therapeutic dose anticoagulation therapy can reduce mortality in …
their skepticism that therapeutic dose anticoagulation therapy can reduce mortality in …
Major Bleeding Events in Hospitalized COVID-19 Patients: A Retrospective Observational Study
A Poloni, G Casalini, G Pozza, A Giacomelli… - Medicina, 2024 - mdpi.com
Thromboprophylaxis/anticoagulation treatment is often required in hospitalized COVID-19
patients. We aimed to estimate the prevalence of major bleeding events in hospitalized …
patients. We aimed to estimate the prevalence of major bleeding events in hospitalized …
Embracing Imatinib: a novel approach to safeguarding the endothelial barrier in patients with COVID-19
Imatinib, an ABL tyrosine-kinase inhibitor, shows promise in restoring endothelial barrier
function in patients with COVID-19, thus, preventing cytokine leakage from the alveolar …
function in patients with COVID-19, thus, preventing cytokine leakage from the alveolar …
Risk factors for thromboembolic events in patients hospitalized for COVID-19 pneumonia in a general ward and requiring treatment with oxygen
R Degrave, J Murris, A Charles-Nelson… - Postgraduate …, 2024 - academic.oup.com
Purpose To assess risk factors for arterial and venous thromboses (AVT) in patients
hospitalized in general wards for COVID-19 pneumonia and requiring oxygen therapy …
hospitalized in general wards for COVID-19 pneumonia and requiring oxygen therapy …
Bleeding and thrombotic events and intensity of heparin therapy in the two first waves of COVID-19
R Rossio, M Tettamanti, AA Galbussera… - Internal and Emergency …, 2024 - Springer
A systemic inflammatory response occurs during SARS-CoV2 infection and is associated
with hypercoagulability and thrombotic events. From March 2020 in our hospital different …
with hypercoagulability and thrombotic events. From March 2020 in our hospital different …
Anticoagulants in Venous Thrombosis, a Pivotal Risk Factor: Authors' Reply
S Soudet, D Basille, H Carette, M Mercier… - …, 2024 - journals.sagepub.com
We are grateful to Dr Chia Sang Kow and colleagues 1 for their interest in our study 2
evaluating the cardiovascular morbidity–mortality at 3 months post-discharge from …
evaluating the cardiovascular morbidity–mortality at 3 months post-discharge from …